JP2020516658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516658A5 JP2020516658A5 JP2019555957A JP2019555957A JP2020516658A5 JP 2020516658 A5 JP2020516658 A5 JP 2020516658A5 JP 2019555957 A JP2019555957 A JP 2019555957A JP 2019555957 A JP2019555957 A JP 2019555957A JP 2020516658 A5 JP2020516658 A5 JP 2020516658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- interleukin
- autoimmune disease
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 9
- 206010003816 Autoimmune disease Diseases 0.000 claims 7
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 7
- 230000002163 immunogen Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000001506 immunosuppresive Effects 0.000 claims 6
- 102100008915 ARG1 Human genes 0.000 claims 4
- 101710038084 ARG1 Proteins 0.000 claims 4
- 102100001825 ARG2 Human genes 0.000 claims 4
- 101700007822 ARG2 Proteins 0.000 claims 4
- 102100007290 CD274 Human genes 0.000 claims 4
- 101710012053 CD274 Proteins 0.000 claims 4
- 102100008614 IDO1 Human genes 0.000 claims 4
- 101710031171 IDO1 Proteins 0.000 claims 4
- 102100008615 IDO2 Human genes 0.000 claims 4
- 101710031174 IDO2 Proteins 0.000 claims 4
- 108010023402 Interleukin 1 Receptor Antagonist Protein Proteins 0.000 claims 4
- 102000016664 Interleukin-1 receptor antagonist Human genes 0.000 claims 4
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 4
- 229940076144 Interleukin-10 Drugs 0.000 claims 4
- 108700000010 Interleukin-35 Proteins 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- 229940028885 Interleukin-4 Drugs 0.000 claims 4
- 102100012588 MOG Human genes 0.000 claims 4
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 4
- 101710004260 Swit_1640 Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 4
- 102100009509 ENTPD1 Human genes 0.000 claims 2
- 101710011427 ENTPD1 Proteins 0.000 claims 2
- 101700079540 FAS Proteins 0.000 claims 2
- -1 FAS-IL Proteins 0.000 claims 2
- 102100008329 FASN Human genes 0.000 claims 2
- 101710008102 FASN Proteins 0.000 claims 2
- 102000000795 Galectin 1 Human genes 0.000 claims 2
- 108010001498 Galectin 1 Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102100004651 LGALS9 Human genes 0.000 claims 2
- 101710015837 LGALS9 Proteins 0.000 claims 2
- 101700037190 NAGS Proteins 0.000 claims 2
- 102100017063 NT5E Human genes 0.000 claims 2
- 101710039712 NT5E Proteins 0.000 claims 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 2
- 108090000854 Oxidoreductases Proteins 0.000 claims 2
- 102100001285 SEMA4A Human genes 0.000 claims 2
- 101710023759 SEMA4A Proteins 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 102100014952 VTCN1 Human genes 0.000 claims 2
- 101700068327 VTCN1 Proteins 0.000 claims 2
- 101710010287 YWHAZ Proteins 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 230000020411 cell activation Effects 0.000 claims 2
- 230000000139 costimulatory Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 239000001272 nitrous oxide Substances 0.000 claims 2
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 101700046422 IFNA Proteins 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 claims 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 1
- 229940045145 Uridine Drugs 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108091005481 innate immune receptors Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (14)
- 自己抗原を含むペプチドまたはポリペプチドをコードする非免疫原性ＲＮＡを含み、前記非免疫原性ＲＮＡが、１−メチルプソイドウリジンの組み込みおよびｄｓＲＮＡの除去によって非免疫原性にされる、治療における使用のための医薬組成物。
- 前記非免疫原性ＲＮＡが、投与されたとき、樹状細胞の活性化、Ｔ細胞の活性化および／またはＩＦＮ−αの分泌をもたらさない、請求項１に記載の使用のための医薬組成物。
- 前記非免疫原性ＲＮＡがインビトロ転写ＲＮＡである、請求項１または２に記載の使用のための医薬組成物。
- 前記自己抗原が自己免疫疾患に関連し、前記自己抗原が好ましくはＴ細胞抗原である、請求項１〜３のいずれか一項に記載の使用のための医薬組成物。
- 前記自己抗原がミエリン抗原であり、前記自己抗原が好ましくはミエリンオリゴデンドロサイト糖タンパク質（ＭＯＧ）またはミエリンオリゴデンドロサイト糖タンパク質（ＭＯＧ）のアミノ酸３５〜５５を含む断片である、請求項１〜４のいずれか一項に記載の使用のための医薬組成物。
- 免疫抑制化合物または前記免疫抑制化合物をコードする非免疫原性ＲＮＡをさらに含み、
前記免疫抑制化合物が、トランスフォーミング成長因子ベータ（ＴＧＦ−β）、インターロイキン１０（ＩＬ−１０）、インターロイキン１受容体拮抗薬（ＩＬ−１ＲＡ）、インターロイキン４（ＩＬ−４）、インターロイキン２７（ＩＬ−２７）、インターロイキン３５（ＩＬ−３５）、プログラム死リガンド１（ＰＤ−Ｌ１）、誘導性Ｔ細胞共刺激リガンド（ＩＣＯＳＬ）、Ｂ７−Ｈ４、ＣＤ３９、ＣＤ７３、ＦＡＳ、ＦＡＳ−ＩＬ、インドールアミン２，３−ジオキシゲナーゼ１（ＩＤＯ１）、インドールアミン２，３−ジオキシゲナーゼ２（ＩＤＯ２）、アセトアルデヒドデヒドロゲナーゼ１（ＡＬＤＨ１）／レチナールアルデヒドデヒドロゲナーゼ（ＲＡＬＤＨ）、アルギナーゼ１（ＡＲＧ１）、アルギナーゼ２（ＡＲＧ２）、亜酸化窒素シンターゼ（ＮＯＳ２）、ガレクチン−１、ガレクチン−９、セマフォリン４Ａからなる群より選択される、請求項１〜５のいずれか一項に記載の使用のための医薬組成物。 - 前記治療が自己免疫疾患の治療または予防を含む、請求項１〜５のいずれか一項に記載の使用のための医薬組成物。
- 前記治療が、自己反応性Ｔ細胞に対する寛容を誘導することを含む、請求項７に記載の使用のための医薬組成物。
- 前記自己免疫疾患がＴ細胞媒介性自己免疫疾患である、請求項７に記載の使用のための医薬組成物。
- 前記自己免疫疾患がＣＮＳの自己免疫疾患である、請求項７に記載の使用のための医薬組成物。
- 前記自己免疫疾患が多発性硬化症である、請求項７に記載の使用のための医薬組成物。
- 前記非免疫原性ＲＮＡが、投与されたとき、樹状細胞の活性化、Ｔ細胞の活性化、および／またはＩＦＮ−αの分泌をもたらさない、請求項７〜１１のいずれか一項に記載の使用のための医薬組成物。
- 前記修飾ヌクレオチドが、自然免疫受容体のＲＮＡ媒介性活性化を抑制する、請求項７〜１２のいずれか一項に記載の使用のための医薬組成物。
- 前記治療が、治療される被験体に、免疫抑制化合物または前記免疫抑制化合物をコードする非免疫原性ＲＮＡを提供することを含み、
前記免疫抑制化合物が、トランスフォーミング成長因子ベータ（ＴＧＦ−β）、インターロイキン１０（ＩＬ−１０）、インターロイキン１受容体拮抗薬（ＩＬ−１ＲＡ）、インターロイキン４（ＩＬ−４）、インターロイキン２７（ＩＬ−２７）、インターロイキン３５（ＩＬ−３５）、プログラム死リガンド１（ＰＤ−Ｌ１）、誘導性Ｔ細胞共刺激リガンド（ＩＣＯＳＬ）、Ｂ７−Ｈ４、ＣＤ３９、ＣＤ７３、ＦＡＳ、ＦＡＳ−ＩＬ、インドールアミン２，３−ジオキシゲナーゼ１（ＩＤＯ１）、インドールアミン２，３−ジオキシゲナーゼ２（ＩＤＯ２）、アセトアルデヒドデヒドロゲナーゼ１（ＡＬＤＨ１）／レチナールアルデヒドデヒドロゲナーゼ（ＲＡＬＤＨ）、アルギナーゼ１（ＡＲＧ１）、アルギナーゼ２（ＡＲＧ２）、亜酸化窒素シンターゼ（ＮＯＳ２）、ガレクチン−１、ガレクチン−９、セマフォリン４Ａからなる群より選択される、請求項７〜１３のいずれか一項に記載の使用のための医薬組成物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022082384A JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
| JP2024025246A JP2024059794A (ja) | 2017-04-11 | 2024-02-22 | 自己免疫疾患の治療のためのｒｎａ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/058651 WO2018188730A1 (en) | 2017-04-11 | 2017-04-11 | Rna for treatment of autoimmune diseases |
| EPPCT/EP2017/058651 | 2017-04-11 | ||
| PCT/EP2018/059188 WO2018189193A1 (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082384A Division JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516658A JP2020516658A (ja) | 2020-06-11 |
| JP2020516658A5 true JP2020516658A5 (ja) | 2021-09-09 |
| JP7078641B2 JP7078641B2 (ja) | 2022-05-31 |
Family
ID=58632945
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555957A Active JP7078641B2 (ja) | 2017-04-11 | 2018-04-10 | 自己免疫疾患の治療のためのｒｎａ |
| JP2022082384A Active JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
| JP2024025246A Pending JP2024059794A (ja) | 2017-04-11 | 2024-02-22 | 自己免疫疾患の治療のためのｒｎａ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082384A Active JP7444924B2 (ja) | 2017-04-11 | 2022-05-19 | 自己免疫疾患の治療のためのｒｎａ |
| JP2024025246A Pending JP2024059794A (ja) | 2017-04-11 | 2024-02-22 | 自己免疫疾患の治療のためのｒｎａ |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11701413B2 (ja) |
| EP (2) | EP3981424A1 (ja) |
| JP (3) | JP7078641B2 (ja) |
| KR (2) | KR20240042138A (ja) |
| CN (2) | CN118161602A (ja) |
| AU (1) | AU2018253352A1 (ja) |
| BR (1) | BR112019020667A8 (ja) |
| CA (1) | CA3059505A1 (ja) |
| CY (1) | CY1124767T1 (ja) |
| DK (1) | DK3609529T3 (ja) |
| ES (1) | ES2893451T3 (ja) |
| HR (1) | HRP20211559T1 (ja) |
| HU (1) | HUE056871T2 (ja) |
| IL (2) | IL269793B (ja) |
| LT (1) | LT3609529T (ja) |
| MX (1) | MX2019012144A (ja) |
| PL (1) | PL3609529T3 (ja) |
| PT (1) | PT3609529T (ja) |
| RS (1) | RS62582B1 (ja) |
| SG (2) | SG11201909520VA (ja) |
| SI (1) | SI3609529T1 (ja) |
| WO (2) | WO2018188730A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220096612A1 (en) * | 2018-11-12 | 2022-03-31 | Translatebioinc | Methods for inducing immune tolerance |
| US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN115232825B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的新冠病毒疫苗 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| BR112023024116A2 (pt) | 2021-05-26 | 2024-02-06 | Imcyse Sa | Métodos de tratamento ou prevenção de doenças autoimunes |
| AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
| CN113336862B (zh) * | 2021-07-05 | 2022-03-01 | 广东省科学院动物研究所 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
| WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| WO2023131254A1 (zh) * | 2022-01-06 | 2023-07-13 | 上海吉量医药工程有限公司 | N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
| AU2002952834A0 (en) * | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| LT2578685T (lt) * | 2005-08-23 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| US8808982B2 (en) * | 2009-12-07 | 2014-08-19 | Cellscript, Llc | Compositions and methods for reprogramming eukaryotic cells |
| WO2012154933A1 (en) * | 2011-05-10 | 2012-11-15 | The Brigham And Women's Hospital, Inc. | Detecting inclusion body myositis |
| WO2013044419A1 (en) * | 2011-09-30 | 2013-04-04 | Beijing Advaccine Biotechnology Co., Ltd. | Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases |
| EP3677678B1 (en) * | 2011-12-30 | 2024-01-31 | Cellscript, Llc | Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| US20160032316A1 (en) * | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| EP3289083A4 (en) | 2015-04-27 | 2018-12-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| CN106395552B (zh) * | 2015-08-03 | 2020-03-17 | 奥的斯电梯公司 | 无绳电梯系统导轨组件 |
| WO2017036889A1 (en) * | 2015-08-28 | 2017-03-09 | Biontech Rna Pharmaceuticals Gmbh | Method for reducing immunogenicity of rna |
| RU2760790C2 (ru) * | 2016-04-22 | 2021-11-30 | Бионтэк Рна Фармасьютикалз Гмбх | Способы получения одноцепочечной рнк |
-
2017
- 2017-04-11 WO PCT/EP2017/058651 patent/WO2018188730A1/en active Application Filing
-
2018
- 2018-04-10 DK DK18717580.7T patent/DK3609529T3/da active
- 2018-04-10 HR HRP20211559TT patent/HRP20211559T1/hr unknown
- 2018-04-10 SG SG11201909520V patent/SG11201909520VA/en unknown
- 2018-04-10 HU HUE18717580A patent/HUE056871T2/hu unknown
- 2018-04-10 CN CN202410206779.6A patent/CN118161602A/zh active Pending
- 2018-04-10 CA CA3059505A patent/CA3059505A1/en active Pending
- 2018-04-10 AU AU2018253352A patent/AU2018253352A1/en active Pending
- 2018-04-10 RS RS20211224A patent/RS62582B1/sr unknown
- 2018-04-10 SG SG10202111163VA patent/SG10202111163VA/en unknown
- 2018-04-10 KR KR1020247008874A patent/KR20240042138A/ko active Search and Examination
- 2018-04-10 KR KR1020197033154A patent/KR20190134765A/ko not_active Application Discontinuation
- 2018-04-10 BR BR112019020667A patent/BR112019020667A8/pt unknown
- 2018-04-10 CN CN201880024391.7A patent/CN110719787B/zh active Active
- 2018-04-10 JP JP2019555957A patent/JP7078641B2/ja active Active
- 2018-04-10 EP EP21191317.3A patent/EP3981424A1/en active Pending
- 2018-04-10 PT PT187175807T patent/PT3609529T/pt unknown
- 2018-04-10 EP EP18717580.7A patent/EP3609529B1/en active Active
- 2018-04-10 WO PCT/EP2018/059188 patent/WO2018189193A1/en unknown
- 2018-04-10 MX MX2019012144A patent/MX2019012144A/es unknown
- 2018-04-10 PL PL18717580T patent/PL3609529T3/pl unknown
- 2018-04-10 SI SI201830424T patent/SI3609529T1/sl unknown
- 2018-04-10 ES ES18717580T patent/ES2893451T3/es active Active
- 2018-04-10 US US16/500,005 patent/US11701413B2/en active Active
- 2018-04-10 LT LTEPPCT/EP2018/059188T patent/LT3609529T/lt unknown
-
2019
- 2019-10-03 IL IL269793A patent/IL269793B/en unknown
-
2021
- 2021-10-06 CY CY20211100867T patent/CY1124767T1/el unknown
-
2022
- 2022-02-28 IL IL290980A patent/IL290980A/en unknown
- 2022-05-19 JP JP2022082384A patent/JP7444924B2/ja active Active
-
2023
- 2023-06-12 US US18/333,273 patent/US20230330198A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025246A patent/JP2024059794A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516658A5 (ja) | ||
| Ocansey et al. | Exosome‐mediated effects and applications in inflammatory bowel disease | |
| Uhlig et al. | Translating immunology into therapeutic concepts for inflammatory bowel disease | |
| Pyle et al. | Early IL-6 signalling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology | |
| HRP20211559T1 (hr) | Rnk za liječenje autoimunih bolesti | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| Hu et al. | The IL‐17 pathway as a major therapeutic target in autoimmune diseases | |
| WO2018204764A1 (en) | Identification and targeted modulation of gene signaling networks | |
| Maynard et al. | Intestinal effector T cells in health and disease | |
| Palomares et al. | Role of Treg in immune regulation of allergic diseases | |
| EP4249053A2 (en) | Microbial consortium and uses thereof | |
| Wakabayashi et al. | Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin | |
| Chen et al. | The role of Th17 cells in inflammatory bowel disease and the research progress | |
| Stojanovska et al. | Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon | |
| Moore et al. | Update in asthma 2009 | |
| WO2017075451A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 | |
| Martinez‐Gonzalez et al. | ILC 2 memory: Recollection of previous activation | |
| Al Ustwani et al. | Genetics on a WHIM | |
| Zundler et al. | Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders | |
| Mascarell et al. | The regulatory dendritic cell marker C1q is a potent inhibitor of allergic inflammation | |
| Lee et al. | Allergy‐related cytokines (IL‐4 and TNF‐α) are induced by Di (2‐ethylhexyl) phthalate and attenuated by plant‐originated glycoprotein (75 kDa) in HMC‐1 cells | |
| Shao et al. | Histone deacetylase 11 inhibits interleukin 10 in B cells of subjects with allergic rhinitis | |
| Burchell et al. | Attenuation of allergen-induced airway hyperresponsiveness is mediated by airway regulatory T cells | |
| Tong et al. | Interleukin‐17A deficiency ameliorates streptozotocin‐induced diabetes | |
| Igaki et al. | Pharmacological evaluation of TAK-828F, a novel orally available RORγt inverse agonist, on murine colitis model |